Activity | Exclusively decentralised (%) | Exclusively on-site (%) | Combination (%) | Not reported (%) |
Outreach | 24 (9.4) | 76 (29.9) | 40 (15.7) | 114 (44.9) |
Prescreening | 29* (11.4) | 57 (22.4) | 11* (4.3) | 157 (61.8) |
Screening | 3 (1.2) | 183 (72) | 9 (3.5) | 59 (23.2) |
Consenting | 7 (2.8) | 226 (89) | 16 (6.3) | 5 (2.0) |
Participant training | 5 (2.0) | 95 (37.4) | 7 (2.8) | 147 (57.9) |
IMP supply† | 7 (2.8) | 108 (42.5) | 10 (3.9) | 13 (5.1) |
IMP adherence monitoring† | 12 (4.7) | 67 (26.4) | 29 (11.4) | 30 (11.8) |
Clinical trial monitoring | 6 (2.4) | 59 (23.2) | 59 (23.2) | 130 (51.2) |
Staff training | 1 (0.4) | 34 (13.4) | 0 (0) | 219 (86.2) |
Data collection | 4 (1.6) | 79 (31.1) | 171 (67.3) | 0 (0) |
Explicit and implicit reporting were aggregated.
*Includes prescreening through medical records.
†Proportions do not add up to 100%, as these trial activities were considered to be ‘not applicable’ for 116 protocols that investigated an IMP that was not administered in an at-home setting.
IMP, investigational medicinal product.